Comparison of cytology, colposcopy, HPV typing and biomarker analysis in cervical neoplasia

Anticancer Research

Volumn 29, Issue 8, 2009, Pages 3401-3409

  Adamopoulou, Maria ^a,b   Kalkani, Eleni ^a   Charvalos, Ekatherina ^a   Avgoustidis, Dimitris ^b   Haidopoulos, Dimitris ^b   Yapijakis, Christos ^b,c  

^a UNIVERSITY OF WEST ATTICA   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Biomarkers; Cervical neoplasia; Colposcopy; HPV typing

Indexed keywords

BIOLOGICAL MARKER; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER INVASION; COLPOSCOPY; CONDYLOMA; CONTROLLED STUDY; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; MOLECULAR TYPING; PAPANICOLAOU TEST; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UTERINE CERVICITIS; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIRUS GENOME; VIRUS TYPING; WART VIRUS;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; DNA, VIRAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 68549087013     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Parkin DM, Pasini P and Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 54: 827-841, 1999.
2. Zur Hausen H: Papillomavirus infections: a major cause of human cancers. Biochem Biophys Acta 1288: F55-78, 1996.
3. Munoz N, Bosch FX, de Sanjose S, Henero R, Castellsague X, Shah KV, Snijders PJ and Meijer CJ: Epidemiological classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527, 2003. (Pubitemid 36159887)
4. Matsukura T and Sugase M: Identification of genital human papillomaviruses in cervical biopsy specimens: segregation of specific virus types in specific clinicopathological lesions. Int J Cancer 61: 13-22, 1995.
5. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Monero V, Kurman R and Shah KV: International biology study on cervical cancer (IBSCC) study group. Prevalence of humanpapillomavirus in cervical cancer: worldwide perspective. J Natl Cancer Inst 87: 796-802, 1995.
6. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W and Kurman RJ: Human papillomavirus infection of the cervix. Relative risk association of fifteen common anogenital types. Obstet Gynecol 79: 328-337, 1992.
7. Bauer HM, Hildesheim A and Schiffman MH: Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis 20: 274-278, 1993. (Pubitemid 23286957)
8. Laara E, Day NE and Hakama M: Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programs. Lancet 1: 1247-1249, 1987. (Pubitemid 17070815)
9. Anderson GH, Boys DA, Benedet JL, Le Riche JC, Matisie JP, Suen KC, Worth AJ, Millner A and Bennett OM: Organisation and results of cervical cytology screening program in British Columbia, 1955-1985. BMJ 296: 975-978, 1988.
10. Lieu D: The Papanicolaou smear: its value and limitations. J Fam Pract 42: 391-399, 1996.
11. Chamberlain J: Reasons that some screening programmes fail to control cervical cancer. In: Screening for Cancer of the Uterine Cervix. Hakama M, Miller A and Day N (eds.). Vol.76: 161-168, 1986 Lyons, France: IARC.
12. Falcone T and Ferenczy A: Cervical intraepithelial neoplasia and condyloma: an analysis of diagnostic accuracy of posttreatment follow-up methods. Am J Obstet Gynecol 154: 260-264, 1986. (Pubitemid 16095398)
13. Kinney WK, Manos MM, Hurley LB and Ransley JE: Where is the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol 91: 973-976, 1998.
14. Wright TC, Jr, Cox JT, Massad LS, Carlson J, Twiggs LB and Wilkinson EJ: 2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia. Am J Obstet Gynecol 189: 295-304, 2003.
15. Monsonego J, Bosch FX, Coursaget P, Cox JT, Franco E, Frazer I, Sankaranarayanan R, Schiller J, Singer A, Wright TC Jr, Kinney W, Meijer CJ, Linder J, McGougan E and Meijer C: Cervical cancer control, properties and new directions. Int J Cancer 108: 329-333, 2004. (Pubitemid 37549596)
16. Hatch KD, Schneider A and Abdel-Nour MW: An evaluation of human papillomavirus testing for intermediate and high-risk types as triage before colposcopy. Am J Obstet Gynecol 172: 1150-1157, 1995.
17. Follen Mitchell M, Schottenfeld D, Tortolero-Luna G, Cantor SB and Richards-Korturn R: Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 91: 626-631, 1998. (Pubitemid 28153058)
18. Huntington J, Oliver LM, St Anna L and Hill J: What is the best approch for patient with ASCUS detected on Pap smear? J Fam Pract 53: 240-241, 2004.
19. Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, and Hiatt RA: Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. J Am Med Assoc 281: 1605-1610, 1999. (Pubitemid 29211769)
20. Cuzick J, Szarewski A, Terry G, Ho L, Hanby A, Maddox P, Anderson M, Kocjan G, Steele ST and Guillebaud J: Human papillomavirus testing in primary cervical screening. Lancet 345: 1533-1536, 1995.
21. Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, Van Ballegooijen M and Van den Akker E: A systematic review of the role of human papillomavirus testing within a cervical screening programme. Technol Assess 3: 1-196, 1999.
22. Committee comments, Survey CYTO-0302-PP gynecologic and non-gynecologic cytology. Toronto, Canada: Quality Management Program Laboratory Services, 2003.
23. Giannoudis A and Herrington SC: Human papillomavirus variants and squamous neoplasia of the cervix. J Pathol 193: 295-302, 2001. (Pubitemid 32229859)
24. Stoler MH: Human papillomavirus and cervical noeplasia: a model for carcinogenesis. Int J Gynecol Pathol 19: 16-28, 2000. (Pubitemid 30010639)
25. Zur hausen H: Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol 186: 131-156, 1994.
26. Galloway DA and Mc Dougall JK: The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia. Semin Cancer Biol 7: 309-315, 1996.
27. Sano T, Oyama T, Kashiwabara K, Fukuda T and Nakajima T: Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical genital lesions. Am J Pathol 153: 1741-1748, 1998. (Pubitemid 28550662)
28. Thomas M, Pin D and Banks L: The role of the E6-P53 interaction in the molecular pathogenesis of HPV. Oncogene 15: 7690-7700, 1999. (Pubitemid 30052696)
29. Crook T, Fisher C, Masterson PJ and Vousden KH: Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene 9: 1225-1230, 1994. (Pubitemid 24095032)
30. Pradip N, Krishnan Nair M, Jayaprakash PG and Radhakrishna Pillai M: Decreased programmed cell death in the uterine cervix associated with high-risk human papillomavirus infection. Pathol Oncol Res 5: 95-103, 1999. (Pubitemid 29352597)
31. Miyashita T, Krajewski S, Krajewski M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of Bcl-2 and base gene expression in vitro and in vivo. Oncogene 9: 1799 - 1805, 1994.
32. Grace Berlin VM, Shalini Veronica J, Iekha Sree TT, Niranjali Devaraj S and Devaraj H: Co-overexpression of p53 and Bcl-2 proteins in HPV-induced squamous cell carcinoma of the uterine cervix. Gynecologic oncology 91: 51-58, 2003.
33. von Knebel Doeberitz M: New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 38: 2229-2242, 2002.
34. Solomon D: The Bethesda system for reporting cervical/vaginal cytological diagnosis. J Am Med Assoc 262: 931-934, 1989.
35. Crum CP, Cibas ES and Lee KR: Pathology of Early Cervical Neoplasia. Churchill Livingstone, London, pp. 29-241, 1997.
36. Vairaktaris E, Yapijakis C, Psirri A, Spiridonidou S, Yannopoulos A, Lazaridis A, Vassiliou S, Ferekidis E, Vylliotis A, Nkenke E and Patsouris E: Loss of tumor suppressor p16 expression in initial stages of oral oncogenesis. Anticancer Res 27: 979-984, 2007. (Pubitemid 46587009)
37. Papakosta V, Vairaktaris E, Vylliotis A, Derka S, Nkenke E, Vassiliou S, Lazaridis A, Mourouzis C, Rallis G, Spiridonidou S, Anagnostopoulou S, Perrea D, Donta I, Yapijakis C and Patsouris E: The co-expression of c-myc and p53 increases and reaches a plateau early in oral oncogenesis. Anticancer Res 26(4B): 2957-2962, 2006. (Pubitemid 44161786)
38. Derka S, Vairaktaris E, Papakosta V, Vassiliou S, Acil Y, Vylliotis A, Spiridonidou S, Lazaris A C, Mourouzis C, Kokkori A, Moulavasili P, Perrea D, Donta I, Yapijakis C and Patsouris E: Cell proliferation and apoptosis culminate in early stages of oral oncogenesis. Oral Oncol 42: 540-550, 2006. (Pubitemid 44304422)
39. Zheng PS, Li SR, Iwasaka T, Song J, Cui MH, Cui MH and Sugimori H: Simultaneous detection by concensus multiplex PCR of high and low-risk and other types of human papillomavirus in clinical samples. Gynecol Oncol 58: 179-183, 1995.
40. Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Delius H, Peyton CL, Bauer HM and Wheeler CM: Identification and assesment of known and novel human papillomavirus by polymerase chain reaction amplification, restriction fragment length polymorphism nucleotide sequence, and phylogenetic algorithms. J Infect Dis 170: 1077-1085, 1994. (Pubitemid 24328606)
41. Vernon SD, Unger ER and Williams S: Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture. J Clin Microbiol 38: 651-655, 2000.
42. Monsonego J, Pinto J, Semaille C, Beumont M, Dachez R, Zerat L, Bianchi A and Franco E: Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intrapithelial neoplasia. Int J Gynecol Cancer 16: 591-598, 2006.
43. Clavel C, Masure M, Bory JP, Putand I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C and Birembaut P: Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 84: 1616-1623, 2001. (Pubitemid 32612492)
44. Cox JT: Management of atypical squamous cells of undetermined significance and low-grade squamous intra-epithelial lesion by human papillomavirus testing. Best Pract Res Clin Obstet Gynaecol 15: 715-741, 2001.
45. Nobbenhuis MAE, Walboomers JMM, Helmerhosrst TJL, Rozendaal L, Remmink J, Risse EKJ, Van der Linden HC, Voorhorst FJ, Kenemans P and Meijer CJLM: Relation of human papillomavirus status to cervical lesions and consequences for cervical cancer screening: a prospective study. Lancet 354: 20-25,1999. (Pubitemid 29304297)
46. Monsonego J, Zerat L, Catalan F and Coscas Y: Genital human papillomavirus infections: correlation of cytological, colposcopic and histological features with viral types in women and their partners. Int J STD AIDS 4: 13-20, 1993. (Pubitemid 23039853)
47. Cox JT: The clinician's view: role of human papillomavirus testing in the American Society for colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors. Arch Pathol Lab Med 127: 950-958, 2003.
48. INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol 58: 525-534, 2005. (Pubitemid 40646875)
49. INK4a and bcl-2 according to HPV type and to the progression of cervical squamous intraepithelial lesions. J Histochem Cytochem 53: 509-516, 2005.
50. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, Dallenbach-Hellweg G, Schmidt D and Von Knebel Doeberitz M: Overexpression of p16 as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 92: 276-284, 2001. (Pubitemid 32225381)
51. KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Arch 439: 55-61, 2001. (Pubitemid 32662518)
52. INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep™ smears. J Clin Pathol 56: 56-63, 2003. (Pubitemid 36132476)
53. Arbyn M and Dillner J: Review of current knowlegde on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 38: 189-197, 2007. (Pubitemid 46275523)
54. Yapijakis C, Adamopoulou M, Antonopoulos G, Koufaliotis N and Vairaktaris E: Prevalence of HPV types in a cohort of Greeks with clinical indication of infection. Anticancer Res 28: 2233-2237, 2008.
55. Panotopoulou E, Tserkezoglou A, Kourousi M, Tsiaousi I, Chatsieleftheriou G, Daskalopoulou D and Magiakos G: Prevalence of human papillomavirus types 6, 11, 16, 18, 31 and 33 in a cohort of Greek women. J Med Virol 79: 1895-1905, 2007.